🧬 WHAT YOU NEED TO KNOW ABOUT JN.1 VARIANT OF COVID-19

1- The JN.1 variant (also known as B.1.1.529.1), a sub-lineage of Omicron, emerged in South Africa in November 2021, and has since been detected in several countries worldwide.

2- It has unique mutations linked to higher transmissibility and potential immune evasion.

3- It spreads rapidly, possibly surpassing earlier variants.

4- People vaccinated or previously infected may still get infected, though having the previous vaccines shots can prevent severe illness related to this variant.

5- Symptoms resemble other COVID-19 variants.

6- Boosters help increase protection.

7- Public health measures like masks, distancing, and vaccines remain crucial.

8- Surveillance tracks its prevalence, guiding health responses.

9- Ongoing research delves into its traits, vaccine efficacy, and new treatment possibilities.

#SARSCoV2 #COVID19 #JN1 #Omicron #ImmuneInvasion #Mutation #Replication #Infectivity #Infection #Vaccination #mRNA

 

Popular posts from this blog

CHROMOSOMAL MICROARRAY VS. WHOLE EXOME SEQUENCING

Image
“𝓜𝓲𝓬𝓻𝓸𝓪𝓻𝓻𝓪𝔂𝓼 𝓱𝓮𝓵𝓹 𝓾𝓼 𝓯𝓲𝓷𝓭 𝓶𝓲𝓼𝓼𝓲𝓷𝓰 𝓸𝓻 𝓮𝔁𝓽𝓻𝓪 𝓬𝓱𝓻𝓸𝓶𝓸𝓼𝓸𝓶𝓪𝓵 𝓹𝓲𝓮𝓬𝓮𝓼; 𝓦𝓔𝓢 𝓽𝓪𝓴𝓮𝓼 𝓾𝓼 𝓭𝓮𝓮𝓹𝓮𝓻, 𝓲𝓷𝓽𝓸 𝓽𝓱𝓮 𝓬𝓸𝓭𝓲𝓷𝓰 𝓻𝓮𝓰𝓲𝓸𝓷𝓼 𝔀𝓱𝓮𝓻𝓮 𝓻𝓪𝓻𝓮 𝓿𝓪𝓻𝓲𝓪𝓷𝓽𝓼 𝓱𝓲𝓭𝓮.” — Ellen Matloff 🧬 Chromosomal Microarray (CMA) and Whole Exome Sequencing (WES) are cornerstones of modern genomic diagnostics. Each offers unique insights: CMA identifies large-scale structural changes like copy number variations (CNVs), while WES investigates the exome; the protein-coding portion where most pathogenic mutations reside. 🔹 CMA is a first-line tool for neurodevelopmental disorders, intellectual disability, and congenital anomalies. It scans for chromosomal imbalances missed by karyotyping, offering ~15–20% diagnostic yield in such cases. Its speed and cost-effectiveness make it a go-to for initial evaluations. 🔹 WES, by contrast, dives into the exonic 1–2% of the genome that harbors ~85% of known disease-causing ...
Read more